Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR∗D study

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressant drugs, have a variable and incomplete efficacy. In order to better understand SSRI action, we explored the hypothesis that SSRIs do not affect mood per se but amplify the influence of the living conditions on mood. To this aim, we exploited the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) data set, selected a subpopulation of 591 patients with an overlapping clinical history and analyzed treatment outcome according to dosage - 20 or 40 mg per day of citalopram. We found that sociodemographic characteristics affected treatment response in the same direction in the two dose groups, but these effects reached statistical significance only in the 40 mg per day dose group. In the latter, higher improvement rate was associated with having a working employment status (P = 0.0219), longer education (P = 0.0053), high income (P = 0.01) or a private insurance (P = 0.0031), and the higher remission rate was associated with having a working employment status (P = 0.0326) or longer education (P = 0.0484). Moreover, the magnitude of the effect of the sociodemographic characteristics on mood, measured as the percent of patients showing a positive outcome when exposed to favorable living conditions, was much greater - up to 37-fold - in the 40 compared to the 20 mg per day dose group. Overall, our results indicate that citalopram amplifies the influence of the living conditions on mood in a dose-dependent manner. These findings provide a potential explanation for the variable efficacy of SSRIs and might lead to the development of personalized strategies aimed at enhancing their efficacy.

Original languageEnglish
Article numbere1066
JournalTranslational Psychiatry
Volume7
Issue number3
DOIs
Publication statusPublished - Mar 21 2017

Fingerprint

Citalopram
Social Conditions
Serotonin Uptake Inhibitors
Depression
Education
Therapeutics
Insurance
Antidepressive Agents

Keywords

  • Antidepressant
  • Neural plasticity
  • drug by environmental interaction

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Biological Psychiatry

Cite this

@article{bc427e86514c4040a6b4e96436f99a36,
title = "Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR∗D study",
abstract = "Selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressant drugs, have a variable and incomplete efficacy. In order to better understand SSRI action, we explored the hypothesis that SSRIs do not affect mood per se but amplify the influence of the living conditions on mood. To this aim, we exploited the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) data set, selected a subpopulation of 591 patients with an overlapping clinical history and analyzed treatment outcome according to dosage - 20 or 40 mg per day of citalopram. We found that sociodemographic characteristics affected treatment response in the same direction in the two dose groups, but these effects reached statistical significance only in the 40 mg per day dose group. In the latter, higher improvement rate was associated with having a working employment status (P = 0.0219), longer education (P = 0.0053), high income (P = 0.01) or a private insurance (P = 0.0031), and the higher remission rate was associated with having a working employment status (P = 0.0326) or longer education (P = 0.0484). Moreover, the magnitude of the effect of the sociodemographic characteristics on mood, measured as the percent of patients showing a positive outcome when exposed to favorable living conditions, was much greater - up to 37-fold - in the 40 compared to the 20 mg per day dose group. Overall, our results indicate that citalopram amplifies the influence of the living conditions on mood in a dose-dependent manner. These findings provide a potential explanation for the variable efficacy of SSRIs and might lead to the development of personalized strategies aimed at enhancing their efficacy.",
keywords = "Antidepressant, Neural plasticity, drug by environmental interaction",
author = "F. Chiarotti and A. Viglione and A. Giuliani and I. Branchi",
year = "2017",
month = "3",
day = "21",
doi = "10.1038/tp.2017.35",
language = "English",
volume = "7",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR∗D study

AU - Chiarotti, F.

AU - Viglione, A.

AU - Giuliani, A.

AU - Branchi, I.

PY - 2017/3/21

Y1 - 2017/3/21

N2 - Selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressant drugs, have a variable and incomplete efficacy. In order to better understand SSRI action, we explored the hypothesis that SSRIs do not affect mood per se but amplify the influence of the living conditions on mood. To this aim, we exploited the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) data set, selected a subpopulation of 591 patients with an overlapping clinical history and analyzed treatment outcome according to dosage - 20 or 40 mg per day of citalopram. We found that sociodemographic characteristics affected treatment response in the same direction in the two dose groups, but these effects reached statistical significance only in the 40 mg per day dose group. In the latter, higher improvement rate was associated with having a working employment status (P = 0.0219), longer education (P = 0.0053), high income (P = 0.01) or a private insurance (P = 0.0031), and the higher remission rate was associated with having a working employment status (P = 0.0326) or longer education (P = 0.0484). Moreover, the magnitude of the effect of the sociodemographic characteristics on mood, measured as the percent of patients showing a positive outcome when exposed to favorable living conditions, was much greater - up to 37-fold - in the 40 compared to the 20 mg per day dose group. Overall, our results indicate that citalopram amplifies the influence of the living conditions on mood in a dose-dependent manner. These findings provide a potential explanation for the variable efficacy of SSRIs and might lead to the development of personalized strategies aimed at enhancing their efficacy.

AB - Selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressant drugs, have a variable and incomplete efficacy. In order to better understand SSRI action, we explored the hypothesis that SSRIs do not affect mood per se but amplify the influence of the living conditions on mood. To this aim, we exploited the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) data set, selected a subpopulation of 591 patients with an overlapping clinical history and analyzed treatment outcome according to dosage - 20 or 40 mg per day of citalopram. We found that sociodemographic characteristics affected treatment response in the same direction in the two dose groups, but these effects reached statistical significance only in the 40 mg per day dose group. In the latter, higher improvement rate was associated with having a working employment status (P = 0.0219), longer education (P = 0.0053), high income (P = 0.01) or a private insurance (P = 0.0031), and the higher remission rate was associated with having a working employment status (P = 0.0326) or longer education (P = 0.0484). Moreover, the magnitude of the effect of the sociodemographic characteristics on mood, measured as the percent of patients showing a positive outcome when exposed to favorable living conditions, was much greater - up to 37-fold - in the 40 compared to the 20 mg per day dose group. Overall, our results indicate that citalopram amplifies the influence of the living conditions on mood in a dose-dependent manner. These findings provide a potential explanation for the variable efficacy of SSRIs and might lead to the development of personalized strategies aimed at enhancing their efficacy.

KW - Antidepressant

KW - Neural plasticity

KW - drug by environmental interaction

UR - http://www.scopus.com/inward/record.url?scp=85017425912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017425912&partnerID=8YFLogxK

U2 - 10.1038/tp.2017.35

DO - 10.1038/tp.2017.35

M3 - Article

C2 - 28323288

AN - SCOPUS:85017425912

VL - 7

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 3

M1 - e1066

ER -